Today: 10 April 2026
Subscribe
Browse Category

Pharmaceutical Industry 31 December 2025 - 16 January 2026

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck shares fell 0.2% to $110.75 Thursday after the FDA delayed decisions in its new voucher fast-track program, according to Reuters. The FDA postponed reviews of drugs from Sanofi, Disc Medicine, and Eli Lilly, citing safety concerns. Investors are watching for Merck’s Feb. 3 earnings and updates on its drug pipeline. Healthcare stocks broadly declined, with Eli Lilly down 3.6%.
15 January 2026
···
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics shares rose 10.6% to $27.59 by midday Wednesday after the company set timelines for key clinical trial readouts in muscle and heart diseases. Top-line data for Becker muscular dystrophy is expected in Q4 2026, with a U.S. drug application planned for early 2027. Investors are watching for Phase 2 and Phase 1 heart program results in the first half of 2026. Trading volume reached about 1 million shares.
14 January 2026
··
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares fell 0.6% to $25.12 in Tuesday afternoon trading after CEO Albert Bourla discussed plans to accelerate obesity drug trials at the J.P. Morgan Healthcare Conference. Bourla said Pfizer aims to launch 10 Phase 3 trials for its Metsera portfolio by 2026 but does not expect revenue growth before 2029. Investors await the Feb. 3 earnings report for updates on the obesity pipeline and guidance.
13 January 2026
···
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics shares fell 56% after the FDA rejected its cell therapy EBVALLO for a rare post-transplant cancer, citing insufficient evidence from the single-arm ALLELE study. The agency said previous manufacturing issues were resolved but requested new efficacy data. Atara and partner Pierre Fabre plan expedited talks with the FDA. The company reported $8.5 million in cash at year-end.
12 January 2026
··
Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Liquidia shares rose 12.9% to $35.86 Friday after the company reported preliminary 2025 YUTREPIA sales of $148.3 million, with $90.1 million in Q4. The company ended 2025 with $190.7 million in cash and over $30 million in positive Q4 cash flow. CEO Roger Jeffs will present at the J.P. Morgan Healthcare Conference on Jan. 14. Audited results are expected in February.
11 January 2026
···
Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific will close its Weaverville, N.C., facility by late 2027, cutting 421 jobs starting December 2026, according to a WARN notice. Shares rose 2.04% Friday to $618.86, near a record high. The company will report earnings Jan. 29 and CEO Marc Casper is scheduled to speak at the J.P. Morgan Healthcare Conference on Jan. 13.
10 January 2026
···
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.
10 January 2026
···
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly shares fell nearly 2% to $1,063.56 Friday, logging a second straight decline after hitting a 52-week high Thursday. The drop followed news that its Zepbound-Taltz drug combo outperformed Taltz alone in a late-stage trial, and a $1.2 billion deal to buy Ventyx Biosciences. Investors are watching for pricing pressures in Europe and key support near $1,060. Lilly’s next earnings call is Feb. 4.
9 January 2026
·
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines shares rose 4.3% to $112.00 Friday after reports that Merck is in talks to buy the company for up to $32 billion. The FDA granted Breakthrough Therapy designation to Revolution’s KRAS-targeting lung cancer drug this week. AbbVie denied involvement in any deal. Revolution declined to comment on the takeover speculation.
9 January 2026
··
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly shares fell 2.1% after hours to $1,085.19 following late-stage data showing its Zepbound-Taltz combo met dual goals in 31.7% of psoriatic arthritis patients, versus 0.8% for Taltz alone. The company also agreed to buy Ventyx Biosciences for $1.2 billion and disclosed a $322.4 million share sale by Lilly Endowment Inc. Investors await updates at the J.P. Morgan Healthcare Conference next week.
9 January 2026
··
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences shares dropped 9.3% to $21.05 Thursday after Morgan Stanley downgraded the stock and cut its price target to $20. The company highlighted a February data update and a Jan. 14 J.P. Morgan conference slot. BlackRock disclosed a 10.4% stake as of Dec. 31. President Juan C. Jaen reported selling 31,823 shares on Jan. 5 under a pre-set trading plan.
8 January 2026
··
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
1 2 3 4 5 … 8

Stock Market Today

  • US Natural Gas Prices Drop Amid Mild Weather and Rising Production Forecasts
    April 10, 2026, 5:08 PM EDT. May Nymex natural gas prices fell 0.82% to a 7.5-month low on Friday, pressured by forecasts of mild U.S. spring weather reducing heating demand. The Commodity Weather Group predicts above-average temperatures across the eastern U.S. through April 19. The U.S. Energy Information Administration (EIA) increased its 2026 dry natural gas production forecast to 109.59 billion cubic feet per day (bcf/d). Current production near record highs and a 2.5-year peak in active rigs further weigh on prices. Despite these bearish cues, limited global liquefied natural gas (LNG) supplies offer medium-term support, worsened by damage at Qatar's Ras Laffan export plant, a key global LNG source. Rising U.S. electricity output and higher-than-expected inventory builds also contribute to downward pressure on gas prices.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 5:08 PM EDT US Natural Gas Prices Drop Amid Mild Weather and Rising Production Forecasts April 10, 2026, 5:08 PM EDT. May Nymex natural gas prices fell 0.82% to a 7.5-month low on Friday, pressured by forecasts of mild U.S. spring weather reducing heating demand. The Commodity Weather Group predicts above-average temperatures across the eastern U.S. through April 19. The U.S. Energy Information Administration (EIA) increased its 2026 dry natural gas production forecast to 109.59 billion cubic feet per day (bcf/d). Current production near record highs and a
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop